packaging issue. The Spine and CMF product category boasted
the most impressive number in terms of a percentage bump—
the segment’s $404 million in sales nearly doubled the amount of
revenue from 2014, with a quite significant 95.2 percent increase.
Products of Note
Though Zimmer and Biomet had their plates full with the inte-
gration of the two companies last year, both entities (and later
the combined force) released a number of noteworthy products
into the market:
• In February 2015, Biomet (still operating as Biomet Or-
thopedics LLC at the time) announced regulatory clear-
ance and first clinical use of Osseo Ti Porous Technology
(a combination of the G7 Osseo Ti shell and Biomet’s G7
Acetabular System) for total hip arthroplasty. Using human
computed tomography data combined with 3D printing
technology, Osseo Ti builds a structure that mimics the ar-
chitecture of human cancellous bone. The porous architec-
ture facilitates creation of complex shapes, and maintains
consistent porosity and strength required to stimulate bone
and tissue ingrowth, as well as implant stability.
• During 2015’s annual meeting of the American Academy of Orthopaedic Surgeons in March, Zimmer Biomet
launched a new external fixation system for trauma
patients. XtraFix is a modular system that lets surgeons
eliminate steps, bars, and clamps from the external fixation process, allowing accommodation of small extremity
fractures in larger constructs. Small and large systems can
be connected with a single clamp.
• In September 2015, the company released the Subchondroplasty Procedure for the foot and ankle. Subchondroplasty
is a minimally invasive outpatient intervention, which
addresses defects relating to subchondral bone marrow lesions—associated with stress fractures or micro-fractures of
the bone adjacent to the joint. Specifically, with a fluoros-copy-assisted procedure, subchondral bone defects are
targeted and filled with AccuFill Bone Substitute Materuak.
It’s usually performed alongside arthroscopy for visualization and treatment of the inner joint.
That’s a fairly impressive launch history for a company wrapped
up in a merger. And there’s more to come— Dvorak hinted during
the company’s third-quarter earnings conference call that Zimmer
Biomet is gearing up for a“powerful pipeline” of products. Dvorak
didn’t dig too deeply into what may come (for competitive reasons)
but offered a glimpse into the company’s long-term strategy.
“I think you’re going to see an incredible cadence of new offerings, by virtue of the combination,” he said during the earnings
call. “What it allows us to do in the intermediate to longer term
is to repurpose dollars into more differentiated innovation, and
get after it in a more aggressive way, addressing unmet clinical
needs because of the scale that we have as a business, not just
in large joints, but in the other product categories that are often-times faster-growing markets.”
4. Smith & Nephew
Olivier Bohuon, CEO
Roberto Quarta, Chairman of the Board
Julie Brown, Chief Financial Officer
Rodrigo Bianchi, President, Asia Pacific and Emerging Markets
Michael Frazzette, Chief Commercial Officer
Diogo Moreira-Rato, President, Europe and Canada
Cyrille Petit, Chief Corporate Development Officer and
President, Global Business Services
Matthew Stober, President, Global Operations
Glenn Warner, President, U.S.
NUMBER OF EMPLOYEES: 15,644
HEADQUARTERS: London, United Kingdom
As an encore to the company’s purchase of ArthroCare in 2014, Smith & Nephew plc announced in October 2015 that it was acquiring Blue Belt Technologies for $275 million. This investment thrust Smith & Nephew into the business of
next-generation robotics-assisted technologies that would further
expand the company’s breadth of orthopedic surgical innovations.
The primary technology windfall for Smith & Nephew was
Blue Belt Technologies’ Navio surgical system, which offers robotics assistance in unicondylar or partial knee replacement surgery. The system features computed tomography-free navigation
software and a unique hand-held, robotic bone-shaping device.
It can also be easily moved throughout a hospital, as it was developed to be a portable solution.
In its rationale for the acquisition, Smith & Nephew represen-
tatives cited several reasons for the transaction:
• It creates a strong combined partial knee portfolio from
which to accelerate growth in the area of partial knee
• Significant further upside anticipated from a range of new
product launches that will expand Navio into indications
beyond partial knees.
• Additional opportunities from using Smith & Nephew’s
global commercial infrastructure to widen adoption of
robotics-assisted technology outside of the United States.
At the time of the announcement, CEO Olivier Bohuon said,
“This acquisition is a compelling strategic move, with the combination of complementary products and R&D programs creating a platform from which we can shape this exciting new area of surgery. It
reinforces our distinctive orthopedic reconstruction strategy, which
combines cutting edge innovation, disruptive business models, and